Found: 222
Select item for more details and to access through your institution.
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
- Published in:
- Journal of Crohn's & Colitis, 2024, v. 18, n. 9, p. 1361, doi. 10.1093/ecco-jcc/jjad213
- By:
- Publication type:
- Article
Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 14, p. 1690, doi. 10.1001/jama.299.14.1690
- By:
- Publication type:
- Article
Transdermal nicotine for mildly to moderately active ulcerative colitis.
- Published in:
- Annals of Internal Medicine, 1997, v. 126, n. 5, p. 364, doi. 10.7326/0003-4819-126-5-199703010-00004
- By:
- Publication type:
- Article
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
- Published in:
- PLoS ONE, 2018, v. 13, n. 5, p. 1, doi. 10.1371/journal.pone.0195123
- By:
- Publication type:
- Article
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820971214
- By:
- Publication type:
- Article
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820971214
- By:
- Publication type:
- Article
The Pharmacokinetics and Colonic Tissue Concentrations of Cyclosporine After IV, Oral, and Enema Administration.
- Published in:
- 1991
- By:
- Publication type:
- Other
Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Cimetidine in Seriously III Patients.
- Published in:
- 1990
- By:
- Publication type:
- Other
Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 65, n. 1, p. 29, doi. 10.1016/S0009-9236(99)70119-0
- By:
- Publication type:
- Article
Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis.
- Published in:
- Clinical Pharmacology & Therapeutics, 1997, v. 61, n. 3, p. 340, doi. 10.1016/S0009-9236(97)90167-3
- By:
- Publication type:
- Article
Innovations in Oral Therapies for Inflammatory Bowel Disease.
- Published in:
- Drugs, 2019, v. 79, n. 12, p. 1321, doi. 10.1007/s40265-019-01169-y
- By:
- Publication type:
- Article
Cyclosporine Enemas for Treatment-Resistant, Mildly to Moderately Active, Left-Sided Ulcerative Colitis.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 1993, v. 88, n. 5, p. 640
- By:
- Publication type:
- Article
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 3, p. 229, doi. 10.1002/cpdd.899
- By:
- Publication type:
- Article
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00212
- By:
- Publication type:
- Article
A randomised, double‐blind, placebo‐controlled study of the LAG‐3‐depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 3, p. 283, doi. 10.1111/apt.17557
- By:
- Publication type:
- Article
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 3, p. 463, doi. 10.1111/apt.16937
- By:
- Publication type:
- Article
Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Cover Image.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. i, doi. 10.1111/apt.16823
- By:
- Publication type:
- Article
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 401, doi. 10.1111/apt.16753
- By:
- Publication type:
- Article
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 464, doi. 10.1111/apt.16712
- By:
- Publication type:
- Article
Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 11, p. 1442, doi. 10.1111/apt.16626
- By:
- Publication type:
- Article
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 10, p. 1108, doi. 10.1111/apt.16328
- By:
- Publication type:
- Article
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 7, p. 784, doi. 10.1111/apt.16248
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 53, n. 3, p. 374, doi. 10.1111/apt.16217
- By:
- Publication type:
- Article
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 11/12, p. 1658, doi. 10.1111/apt.16119
- By:
- Publication type:
- Article
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 10, p. 1574, doi. 10.1111/apt.16083
- By:
- Publication type:
- Article
Long‐term safety of vedolizumab for inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 8, p. 1353, doi. 10.1111/apt.16060
- By:
- Publication type:
- Article
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 6, p. 1008, doi. 10.1111/apt.16026
- By:
- Publication type:
- Article
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 568, doi. 10.1111/apt.15919
- By:
- Publication type:
- Article
No benefit of continuing vs stopping 5‐aminosalicylates in patients with ulcerative colitis escalated to anti‐metabolite therapy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 481, doi. 10.1111/apt.15876
- By:
- Publication type:
- Article
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1209, doi. 10.1111/apt.15735
- By:
- Publication type:
- Article
Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1047, doi. 10.1111/apt.15726
- By:
- Publication type:
- Article
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1031, doi. 10.1111/apt.15719
- By:
- Publication type:
- Article
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 10, p. 997, doi. 10.1111/apt.15716
- By:
- Publication type:
- Article
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 5, p. 553, doi. 10.1111/apt.15609
- By:
- Publication type:
- Article
Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 4, p. 435, doi. 10.1111/apt.15577
- By:
- Publication type:
- Article
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 2, p. 271, doi. 10.1111/apt.15555
- By:
- Publication type:
- Article
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 10, p. 1068, doi. 10.1111/apt.15514
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 8, p. 848, doi. 10.1111/apt.15484
- By:
- Publication type:
- Article
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 11, p. 1401, doi. 10.1111/apt.15250
- By:
- Publication type:
- Article
Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 9, p. 1188, doi. 10.1111/apt.15214
- By:
- Publication type:
- Article
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 85, doi. 10.1007/s40259-021-00512-8
- By:
- Publication type:
- Article
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
- Published in:
- BioDrugs, 2021, v. 35, n. 6, p. 715, doi. 10.1007/s40259-021-00507-5
- By:
- Publication type:
- Article
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab.
- Published in:
- Annals of Internal Medicine, 2007, v. 146, n. 12, p. 829, doi. 10.7326/0003-4819-146-12-200706190-00159
- By:
- Publication type:
- Article
Diagnosis and Treatment of Perianal Fistulas in Crohn Disease.
- Published in:
- Annals of Internal Medicine, 2001, v. 135, n. 10, p. 906, doi. 10.7326/0003-4819-135-10-200111200-00011
- By:
- Publication type:
- Article
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2015, v. 110, n. 6, p. 802, doi. 10.1038/ajg.2015.120
- By:
- Publication type:
- Article
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2014, v. 109, n. 11, p. 1771, doi. 10.1038/ajg.2014.242
- By:
- Publication type:
- Article
Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2014, v. 109, n. 7, p. 994, doi. 10.1038/ajg.2014.110
- By:
- Publication type:
- Article